Back to top
more

Iovance Biotherapeutics (IOVA)

(Real Time Quote from BATS)

$8.44 USD

8.44
4,068,203

+0.38 (4.72%)

Updated Aug 25, 2026 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

by Zacks Equity Research

Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.

Zacks Equity Research

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.

Kinjel Shah headshot

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

by Kinjel Shah

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

Zacks Equity Research

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

by Zacks Equity Research

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

by Zacks Equity Research

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

Zacks Equity Research

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Iovance (IOVA) Might Surprise This Earnings Season

by Zacks Equity Research

Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

by Zacks Equity Research

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.